RESUMO
Previous studies in Western diet (WD)-fed male rats have highlighted a link between the stimulation of cardiac contractility, mitochondrial adaptations and a pro-inflammatory fatty acid profile of phospholipids in the heart. Our objectives were to determine (1) if WD-fed female Wistar rats and obese humans display a similar pro-inflammatory profile in their cardiac phospholipids and (2) if this lipid profile is associated with deleterious effects on the heart of the female rodents. Female Wistar rats were fed WD for 5 weeks or a laboratory chow as a control. Ionic homeostasis, redox status, inflammation markers, and fatty acid composition of phospholipids were analysed in the heart. WD increased the abdominal fat mass without modifying the body weight of female rats. As previously found in males, a WD induced a shift in membrane fatty acid composition toward a pro-inflammatory profile in the female rats, but not in obese humans. It was associated with an increased COX2 expression suggesting an increased pro-inflammatory eicosanoid production. Signs of increased intracellular calcium strongly supported a stimulation of cardiac contractility without any induction of apoptosis. The heart of WD-fed rats exhibited a hypoxic state as a higher HIF1-α expression was reported. The expressions of antioxidant enzymes were increased, but the redox reserves against reactive oxygen species were lowered. In conclusion, as previously observed in males, we suppose that cardiac abnormalities are magnified with severe obesity in female rats, leading to hypoxia and intense oxidative stress which could ultimately induce cell death and heart failure.
Assuntos
Dieta Ocidental , Hipóxia , Contração Miocárdica , Ratos Wistar , Animais , Feminino , Dieta Ocidental/efeitos adversos , Hipóxia/metabolismo , Hipóxia/fisiopatologia , Miocárdio/metabolismo , Subunidade alfa do Fator 1 Induzível por Hipóxia/metabolismo , Ratos , Ciclo-Oxigenase 2/metabolismo , Estresse Oxidativo , Fosfolipídeos/metabolismo , Obesidade/metabolismo , Obesidade/etiologia , Obesidade/fisiopatologia , Modelos Animais de Doenças , Masculino , HumanosRESUMO
OBJECTIVES: To evaluate the occurrence of plasmid-mediated fos genes among fosfomycin-resistant Escherichia coli isolates collected from patients in Lisbon, Portugal, and characterize the fos-positive strains. METHODS: A total of 19 186 E. coli isolates were prospectively collected between April 2022 and January 2023 from inpatients and outpatients at a private laboratory in Lisbon. Fosfomycin resistance was initially assessed by semi-automated systems and further confirmed by the disc diffusion method. Resistant isolates were investigated for plasmid-mediated fos genes (fosA1-fosA10, fosC and fosL1-fosL2) and extended-spectrum beta-lactamases (ESBLs) by PCR and sequencing. Multilocus sequence typing was performed to evaluate the clonal relationship among fos-carrying isolates. RESULTS: Out of the 19 186 E. coli isolates, 100 were fosfomycin-resistant (0.5%), out of which 15 carried a fosA-like gene (15%). The most prevalent fosfomycin-resistant determinant was fosA3 (n = 11), followed by fosA4 (n = 4). Among the 15 FosA-producing isolates, 10 co-produced an ESBL (67%), being either of CTX-M-15 (n = 8) or CTX-M-14 (n = 2) types. The fosA3 gene was carried on IncFIIA-, IncFIB-, and IncY-type plasmids, whereas fosA4 was always located on IncFIB-type plasmids. Most FosA4-producing isolates belonged to a single sequence type ST2161, whereas isolates carrying the fosA3 gene were distributed into nine distinct genetic backgrounds. CONCLUSION: The prevalence of fosfomycin-resistant E. coli isolates is still low in Portugal. Notably, 15% of fosfomycin-resistant isolates harbour a transferable fosA gene, among which there is a high rate of ESBL producers, turning traditional empirical therapeutical options used in Portugal (fosfomycin and amoxicillin-clavulanic acid) ineffective.
Assuntos
Infecções por Escherichia coli , Fosfomicina , Humanos , Fosfomicina/farmacologia , Escherichia coli/genética , Antibacterianos/farmacologia , Portugal/epidemiologia , Genes fos , Infecções por Escherichia coli/epidemiologia , DNA Bacteriano/genética , beta-Lactamases/genética , Plasmídeos/genéticaRESUMO
AIMS: To assess EuroSCORE performance in predicting in-hospital mortality in on-pump coronary artery bypass grafting (CABG) and off-pump coronary artery bypass grafting (OPCAB). METHODS AND RESULTS: Additive and logistic EuroSCORE were computed for consecutive patients undergoing CABG (n = 3440, 75%) or OPCAB (n = 1140, 25%) at our hospital from 1999 to September 2007. The areas under the receiver operating characteristic (ROC) curves (AUCs) were used to describe performance and accuracy. No difference in performance between CABG and OPCAB and between additive and logistic EuroSCORE (additive EuroSCORE AUCs of 0.808 and 0.779 for CABG and OPCAB, respectively; logistic EuroSCORE AUCs of 0.813 and of 0.773 for CABG and OPCAB, respectively) was found, although a marked tendency to overpredict mortality by both models was evident. A meta-analysis of previously published data was done, and a total of eight studies representing 19 212 and 5461 patients undergoing CABG and OPCAB, respectively, met inclusion criteria. Meta-analysis confirmed similar performance of EuroSCORE in CABG and OPCAB: estimated AUCs were 0.767 and 0.766 for CABG and OPCAB, respectively, with an estimated difference of 0.001 (95% CI -0.061 to 0.063). CONCLUSION: Additive and logistic EuroSCORE algorithms performed similarly, and cumulative evidence suggests comparable performance in CABG and OPCAB procedures; both risk models, however, significantly overestimated mortality.
Assuntos
Ponte de Artéria Coronária/mortalidade , Doença das Coronárias/cirurgia , Idoso , Ponte Cardiopulmonar/mortalidade , Ponte de Artéria Coronária sem Circulação Extracorpórea/mortalidade , Doença das Coronárias/mortalidade , Métodos Epidemiológicos , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , PrognósticoRESUMO
Evaluating the activity of cardiac mitochondria is probably the best way to estimate early cellular damage in chronic pathology. Early diagnosis allows rapid therapeutic intervention thus increasing patient survival rate in a number of diseases. However, data on human cardiac mitochondria are scarce in the international literature. Here, we describe a method to extract and study functional mitochondria from the small-sized right atrial aliquots (minimum of 400 mg) obtained during extracorporeal circulation and usually considered as surgical waste products. The mitochondria were purified through several mechanical processes (fine myocardial cutting, tissue grinding and potter Elvehjem homogenising), an enzymatic proteolytic action (subtilisin) and differential centrifugations. In chronic pathologies, including obesity, early disturbances of mitochondrial function can occur. The effects of obesity on the rate of mitochondrial oxygen consumption and H2O2 release were thus determined with three different substrates (glutamate/malate, succinate/rotenone and palmitoylcarnitine/malate). The human atrial mitochondria were of high quality from a functional viewpoint, compared to rat ventricle organelles, but the extraction yield of the human mitochondria was twice lower than that of rat mitochondria. Tests showed that glutamate/malate-related ADP-stimulated respiration was strongly increased in obese subjects, although the oxidation of the other two substrates was unaffected. Reactive oxygen species (ROS) production by the isolated mitochondria was low in comparison with that of the lean subjects. These results confirm those found in one of our previous studies in the ventricles of rats fed a high-fat diet. In conclusion, the described method is simple, reliable and sensitive. It allows for the description of the impact of obesity on the function of atrial mitochondria while using only a small patient sampling (n = 5 in both the lean and the obese groups).
Assuntos
Peróxido de Hidrogênio , Consumo de Oxigênio , Animais , Humanos , Obesidade , Ratos , Espécies Reativas de Oxigênio , RotenonaRESUMO
Primary cardiac lymphoma is a neoplasm with poor prognosis. It is occasionally seen in patients with AIDS and transplant recipients, and it is exceedingly rare in nonimmunocompromised hosts. Presentation is heterogeneous and nonspecific, making clinical suspicion difficult. Diagnosis is often late. There are different therapeutic options (chemotherapy, radiotherapy, monoclonal antibodies therapy, and surgery), but there is no uniform consent on the best management. Surgical treatment is controversial. We report our experience with a unique patient in 23 years.
Assuntos
Neoplasias Cardíacas/terapia , Linfoma/terapia , Idoso , Neoplasias Cardíacas/imunologia , Neoplasias Cardíacas/patologia , Humanos , Imunocompetência , Linfoma/imunologia , Linfoma/patologia , MasculinoRESUMO
The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.
Assuntos
Anti-Inflamatórios/efeitos adversos , Anticorpos Monoclonais Humanizados/efeitos adversos , Sarcoidose/tratamento farmacológico , Dermatopatias/tratamento farmacológico , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Adalimumab , Biópsia , Progressão da Doença , Feminino , Humanos , Pessoa de Meia-Idade , Sarcoidose/patologia , Dermatopatias/patologia , Resultado do TratamentoRESUMO
The paradoxical adverse effects of tumor necrosis factor-alpha (TNF-alpha) antagonists have been described frequently as a result of the widespread use of these drugs. Among the TNF-alpha blocking agents, few reports exist relating the use of adalimumab in cutaneous sarcoidosis, although all of them show good results. More recently, sarcoidosis onsets have been reported with various TNF-alpha inhibitors. The current case is, to our knowledge, the first to describe the exacerbation of cutaneous lesions of sarcoidosis treated with adalimumab.
Os efeitos paradoxais dos anti-TNF-alpha têm sido cada vez mais descritos com a utilização mais ampla dessas drogas. Entre os TNF-alpha, registam-se poucos casos com a utilização de adalimumab no tratamento da sarcoidose cutânea, sendo que todos eles apresentam bons resultados. Têm sido descritos, mais recentemente, casos de sarcoidose induzidos por vários anti-TNF-alpha. O presente caso é, até à data, o primeiro a descrever a exacerbação de lesões cutâneas de sarcoidose tratadas com adalimumab.